A series of large-scale randomized controlled trials (RCTs) demonstrated that SGLT2i use reduced the risk of kidney disease progression in patients with and without diabetes ( post hoc analysis of SUSTAIN6 and PIONEER6 demonstrated that semaglutide slowed the eGFR decline in T2D patients with a high risk of CVD ( With combination therapy of SGLT2i and GLP1Ra, the preceding drug did not affect the renal outcome in the main analysis of RECAP study ( post hoc analysis, the SGLT2i-preceding group had a slower rate of eGFR decline in comparison to the GLP1Ra-preceding group, and multiple regression analysis identified the preceding of SGLT2i as an independent and significant factor of change in eGFR decline
Brain function Low levels of vitamin B12 have been linked to a decline in brain function
[DOI] [PMC free article] [PubMed] [Google Scholar] 95.Lee Y.J., Yoon E., Park S., Kim Y.W., Kim S.E., Ko J., Park J.H., Park K.M., Kim I.H., Park B.S
Ameliorative Effects Of N-Acetylcysteine As Adjunct Therapy On Symptoms Of Painful Diabetic Neuropathy
Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved for weight management in adults with obesity or overweight with a weight-related health condition, regardless of whether diabetes is present
36 DIAGNOSIS OF DRUG-INDUCED PANCREATITIS The diagnosis of drug-induced acute pancreatitis first requires a diagnosis of acute pancreatitis
